USPTO serial 99105786
YGX
Reviewed by CopyMark Law Group
- Filing date
- Status date
- Registration date
- Nov 3, 2026
- Examiner
- KONSCHAK, CARL A
- Law office
- INTENT TO USE SECTION
What this means
Status 700 means the trademark is registered and active on the Principal Register. You have nationwide rights for the listed goods and services and may use ®. Section 8 maintenance is due between years five and six. Calendar Section 8 between years five and six, and consider trademark monitoring.
Need help with YGX?
If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.
Current trademark owner
Monitor this mark, or talk with CopyMark about this registration.
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.
Owner
Shankill, Dublin, IE
Shankill, Dublin, IE
Shankill, Dublin, IE
Attorney of record
The USPTO lists this attorney as the applicant's representative for correspondence on this application.
Eryn Y. Truong
Eryn Y. Truong LOZA & LOZA, LLP305 N. Second Ave., #127Upland, CA 91786United StatesGoods and services
| Class | Description | Status | First use |
|---|---|---|---|
| 005 | Pharmaceutical preparations for the treatment of oncological, hematological, immunological, neurological, cardiovascular, metabolic, infectious, inflammatory, dermatological, gastrointestinal, hepatic, respiratory, renal, ophthalmic, and musculoskeletal diseases and disorders in humans; Veterinary pharmaceutical preparations for the treatment of oncological, hematological, immunological, neurological, cardiovascular, metabolic, infectious, inflammatory, dermatological, gastrointestinal, hepatic, respiratory, renal, ophthalmic, and musculoskeletal diseases and disorders in animals | ACTIVE | — |
| 042 | Pharmaceutical research services; Pharmaceutical product evaluation; Research in the field of pharmaceuticals; Research relating to pharmaceuticals; Pharmaceutical research and development services; Research on the subject of pharmaceuticals; Laboratory research services relating to pharmaceuticals; Research and development of new products for the pharmaceutical industry; Consultancy in the field of pharmaceutical research; Consultancy relating to pharmaceutical research and development; Laboratory research in the field of pharmaceuticals; Technical research in the field of pharmaceuticals; Research and development in the pharmaceutical and biotechnology fields; Providing scientific research information in the field of pharmaceuticals and clinical trials; Pharmaceutical products development; Pharmaceutical drug development services; Development of pharmaceutical preparations and medicines; Consultancy in the field of biotechnology; Consultancy relating to biotechnology; Biotechnology testing; Biotechnology research; Research relating to biotechnology; Scientific research; Scientific testing services in the field of pharmaceuticals; Scientific research services; Scientific research consulting; Scientific laboratory services | ACTIVE | — |
| 044 | Medical services in the nature of pharmaceutical consultation; Pharmaceutical advice; Pharmaceutical advisory services; Provision of pharmaceutical information, namely, providing information relating to diagnostic, prophylactic and therapeutic properties of pharmaceuticals | ACTIVE | — |
| 045 | Intellectual property consultation; Intellectual property consultancy; Intellectual property licensing services; Management of intellectual property; Licensing of intellectual property; Licensing of intellectual property rights; Consultancy relating to intellectual property management; Intellectual property management services; Advisory services relating to intellectual property rights; Consultancy relating to the licensing of intellectual property; Intellectual property consultancy services for universities and research institutions | ACTIVE | — |
Related trademarks
CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.
- Other trademarks owned by YGIX Medicines Limited
- Other trademarks owned by YGIX Medicines Limited
- Other trademarks owned by YGIX Medicines Limited
- Other trademarks in Class 005
- Other trademarks in Class 042
- Other trademarks in Class 044
- Other trademarks in Class 045
- Similar marks named YGX
- Recently changed USPTO trademarks
- Recently filed trademarks
- Browse all trademark records
Prosecution history
| Date | Code | Event | What it means |
|---|---|---|---|
| Nov 3, 2026 | NRCC | NOTICE OF REGISTRATION CONFIRMATION EMAILED | — |
| Nov 3, 2026 | R.PR | REGISTERED-PRINCIPAL REGISTER | Your trademark is registered on the Principal Register — the strongest form of federal trademark protection. You may use the ® symbol for the covered goods and services. Maintenance filings (Section 8 and renewals) are required to keep the registration alive. |
| Oct 14, 2026 | DP1B | 1(B) BASIS DELETED; PROCEED TO REGISTRATION | — |
| Oct 14, 2026 | IUCN | NOTICE OF ALLOWANCE CANCELLED | — |
| Apr 21, 2026 | EPPA | TEAS POST PUBLICATION AMENDMENT RECEIVED | — |
| Apr 21, 2026 | NOAM | NOA E-MAILED - SOU REQUIRED FROM APPLICANT | A Notice of Allowance means your intent-to-use application cleared examination and opposition but is not registered yet. You must file a Statement of Use showing the mark in commerce, or request an extension, before the deadline — usually six months from the notice date. |
| Feb 24, 2026 | NPUB | OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED | — |
| Feb 24, 2026 | PUBO | PUBLISHED FOR OPPOSITION | Your mark was published in the USPTO Official Gazette for a 30-day opposition window. During that period, third parties who believe they would be harmed can file an opposition. If no opposition is filed, prosecution usually continues toward registration or a Notice of Allowance. |
| Feb 18, 2026 | NONP | NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED | — |
| Jan 29, 2026 | CNSA | APPROVED FOR PUB - PRINCIPAL REGISTER | — |
| Jan 23, 2026 | TEME | TEAS/EMAIL CORRESPONDENCE ENTERED | — |
| Jan 23, 2026 | CRFA | CORRESPONDENCE RECEIVED IN LAW OFFICE | — |
| Jan 23, 2026 | ERFR | TEAS REQUEST FOR RECONSIDERATION RECEIVED | — |
| Nov 4, 2025 | GNFN | NOTIFICATION OF FINAL REFUSAL EMAILED | — |
| Nov 4, 2025 | GNFR | FINAL REFUSAL E-MAILED | A final Office Action (final refusal) means the examining attorney is maintaining at least one refusal and your options are narrower. You can file a response addressing the refusal, appeal to the Trademark Trial and Appeal Board, or let the application abandon. |
| Nov 4, 2025 | CNFR | FINAL REFUSAL WRITTEN | A final Office Action (final refusal) means the examining attorney is maintaining at least one refusal and your options are narrower. You can file a response addressing the refusal, appeal to the Trademark Trial and Appeal Board, or let the application abandon. |
| Oct 31, 2025 | TEME | TEAS/EMAIL CORRESPONDENCE ENTERED | — |
| Oct 31, 2025 | CRFA | CORRESPONDENCE RECEIVED IN LAW OFFICE | — |
| Oct 31, 2025 | TROA | TEAS RESPONSE TO OFFICE ACTION RECEIVED | This event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action. |
| Aug 26, 2025 | GNRN | NOTIFICATION OF NON-FINAL ACTION E-MAILED | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Aug 26, 2025 | GNRT | NON-FINAL ACTION E-MAILED | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Aug 26, 2025 | CNRT | NON-FINAL ACTION WRITTEN | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Aug 26, 2025 | DOCK | ASSIGNED TO EXAMINER | — |
| Jul 11, 2025 | NWOS | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED | — |
| Mar 26, 2025 | MAFR | APPLICATION FILING RECEIPT MAILED | — |
| Mar 26, 2025 | NWAP | NEW APPLICATION ENTERED | — |